WuXi PharmaTech and Foundation Partner to Offer Cancer Test in China

WuXi PharmaTech formed a collaboration with Foundation Medicine of Cambridge, MA that will offer the FoundationOne® assay in China. The assay tests for genetic abnormalities associated with cancer to determine the best treatment. For pharmas undertaking China clinical trials, the personalized medicine test will identify target patient populations. WuXi, whose venture arm was an early investor in Foundation, will perform the laboratory component of the assay at its Shanghai Genome Center. More details.... Stock Symbols: (NYSE: WX) (NSDQ: FMI) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.